Share ownership BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 02:56:41 11/07/2025 pm IST			5-day change	1st Jan Change
188.15 ^SEK	-0.82%		+3.07%	-5.61%

17/06	Lannebo Sverige Plus increased by 4.3 percent in May – rising profitability at Elekta	FW
13/06	BioArctic to Advance Parkinson's Disease Drug Trial After Positive Safety Review	MT

Share class: BioArctic AB

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	1,43,99,996	0	0	44.08 %
Stock B	1	7,39,89,039	3,89,58,857 ( 52.65 %)	0

Major shareholders: BioArctic AB

Name	Equities	%	Valuation
Lars Gunnar Lannfelt 28.35 %	2,08,85,052	28.35 %	392 M kr
Pär Lars Gellerfors 18.11 %	1,33,43,201	18.11 %	250 M kr
Fjärde AP-fonden 7.356 %	54,18,493	7.356 %	102 M kr
Swedbank Robur Fonder AB 4.252 %	31,31,849	4.252 %	59 M kr
RA Capital Management LP 4.233 %	31,17,736	4.233 %	58 M kr
Unionen 3.394 %	25,00,000	3.394 %	47 M kr
Nordea Investment Management AB 2.985 %	21,98,679	2.985 %	41 M kr
Tredje AP-fonden 1.621 %	11,94,212	1.621 %	22 M kr
Investment AB Öresund (Investment Company) 1.154 %	8,50,000	1.154 %	16 M kr
Indecap Fonder AB 0.7038 %	5,18,453	0.7038 %	10 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Lars Gunnar Lannfelt 60 %	86,39,998	60 %	162 M kr
Pär Lars Gellerfors 40 %	57,59,998	40 %	108 M kr

Breakdown by shareholder type

Individuals	66.38%
Institutional	23.12%
Other	3.39%
Unknown	7.11%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	66.38%
Sweden	21.8%
United States	4.27%
Norway	0.27%
Netherlands	0.08%
Finland	0.07%
Ireland	0.01%
Denmark	0.01%

Based on 1000 largest holdings

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Employees

116

Sector

Biotechnology & Medical Research

Calendar

28/08 - Q2 2025 Earnings Release

More about the company